Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery


ISSN (Print): 1574-8928
ISSN (Online): 2212-3970


The Non-hodgkin Lymphoma Treatment and Side Effects: A Systematic Review and Meta-analysis

Author(s): Alice Barros Câmara* and Igor Augusto Brandão

Volume 19, Issue 1, 2024

Published on: 08 February, 2023

Page: [93 - 120] Pages: 28

DOI: 10.2174/1574892818666230117151757

Price: $65


Objectives: This paper aims to review studies regarding side effects found during Non- Hodgkin Lymphoma treatment, to suggest the drug class most associated with these effects, as well as the most prevalent side effect grade.

Methods: This review is registered in PROSPERO (IDCRD42022295774) and followed the PICOS strategy and PRISMA guidelines. The search was carried out in the databases PubMed/ MEDLINE, Scientific Electronic Library Online, and DOAJ. Medical Subject Headings Terms were used and quantitative studies with conclusive results regarding side effects during the non-Hodgkin lymphoma treatment were selected. Patent information was obtained from google patents.

Results: Monoclonal antibodies were the main drug class associated with side effects during NHL therapy. The combination of Rituximab (Rituxan®; patent EP1616572B) and iInotuzumab (Besponsa ®; patent EP1504035B3) was associated with a higher incidence of thrombocytopenia (p < 0.05), while the combination of Rituximab and Venetoclax (Venclexta®; patent CN107089981A) was associated with a higher incidence of neutropenia (p < 0.05) when compared to Bendamustine combinations (Treanda™; patent US20130253025A1). Meta-analysis revealed a high prevalence of grade 3-4 neutropenia and thrombocytopenia in men. Finally, Americans and Canadians experienced a higher prevalence of these side effects, when compared to others nationalities (p < 0.05).

Conclusion: Patents regarding the use of monoclonal antibodies in NHL treatment were published in the last year. Monoclonal antibodies associated with neutropenia (grade 3-4) and thrombocytopenia, especially in North American men treated for NHL, and with an average age of 62 years demonstrated importance in this study.

Keywords: Neutropenia, thrombocytopenia, monoclonal antibodies, side effect grade, nationality, gender.

Skibola CF, Curry JD, Nieters A. Genetic susceptibility to lymphoma. Haematologica 2007; 92(7): 960-9.
[] [PMID: 17606447]
Bateman AC, Howell WM. Human leukocyte antigens and cancer: is it in our genes? J Pathol 1999; 188(3): 231-6.
[<231:AID-PATH325>3.0.CO;2-A] [PMID: 10419588]
Rothman N, Skibola CF, Wang SS, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 2006; 7(1): 27-38.
[] [PMID: 16389181]
Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet 2012; 380(9844): 848-57.
[] [PMID: 22835603]
Clifford G, Franceschi S, Grulich AE, Van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370(9581)
[PMID: 17617251]
Shiels MS, Engels EA, Linet MS, et al. The epidemic of non-Hodgkin lymphoma in the United States: disentangling the effect of HIV, 1992-2009. Cancer Epidemiol Biomarkers Prev 2013; 22(6): 1069-78.
[] [PMID: 23595542]
Palackdharry CS. The epidemiology of non-Hodgkin’s lymphoma: why the increased incidence? Oncology 1994; 8(8): 67-73.
[PMID: 7947004]
Chiu BCH, Hou N. Epidemiology and etiology of non-hodgkin lymphoma. Non-Hodgkin Lymphoma. Cham, Switzerland: Springer 2015; Vol. 165: pp. 1-25.
Hartge P. Non-hodgkin lymphoma. Cancer epidemiology and prevention. (3rd ed.). New York: Oxford University Press 2006; pp. 898-918.
Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127(20): 2375-90.
[] [PMID: 26980727]
Ansell SM, Armitage J. Non-Hodgkin lymphoma: Diagnosis and treatment. Mayo Clin Proc 2005; 80(8): 1087-97.
[] [PMID: 16092591]
Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med 1998; 339(1): 21-6.
[] [PMID: 9647875]
Pfreundschuh M, Ho AD, Cavallin-Stahl E, et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol 2008; 9(5): 435-44.
[] [PMID: 18400558]
Lamy T, Damaj G, Gyan E, et al. R-CHOP with or without radiotherapy in non-bulky limited-stage diffuse large B cell lymphoma (DLBCL): preliminary results of the prospective randomized phase III 02-03 trial from the lysa/goelams group. Blood 2014; 124(21): 393.
Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005; 23(18): 4117-26.
[] [PMID: 15867204]
Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 2013; 381(9880): 1817-26.
[] [PMID: 23615461]
Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24(19): 3121-7.
[] [PMID: 16754935]
Kahl BS, Hong F, Williams ME, et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol 2014; 32(28): 3096-102.
[] [PMID: 25154829]
a) Flinn IW, Miller CB, Ardeshna KM, et al. DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol 2019; 37(11): 912-22.
[] [PMID: 30742566];
b) Sehn LH, Chua N, Mayer J, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol 2016; 17(8): 1081-93.
[] [PMID: 27345636]
Palanca-Wessels MCA, Czuczman M, Salles G, et al. Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol 2015; 16(6): 704-15.
[] [PMID: 25925619]
Kuruvilla J, Savona M, Baz R, et al. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood 2017; 129(24): 3175-83.
[] [PMID: 28468797]
Goebeler ME, Knop S, Viardot A, et al. Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study. J Clin Oncol 2016; 34(10): 1104-11.
[] [PMID: 26884582]
Nastoupil LJ, Lunning MA, Vose JM, et al. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Lancet Haematol 2019; 6(2): e100-9.
[] [PMID: 30709431]
Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014; 370(11): 1008-18.
[] [PMID: 24450858]
Moreno V, Sepulveda JM, Vieito M, et al. Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin’s lymphoma. Ann Oncol 2020; 31(6): 780-8.
[] [PMID: 32240793]
Patnaik A, Appleman LJ, Tolcher AW, et al. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin’s lymphomas. Ann Oncol 2016; 27(10): 1928-40.
[] [PMID: 27672108]
Pettengell R, Coiffier B, Narayanan G, et al. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol 2012; 13(7): 696-706.
[] [PMID: 22652183]
Dang NH, Ogura M, Castaigne S, et al. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol 2018; 182(4): 583-6.
[] [PMID: 28677896]
Fowler NH, Davis RE, Rawal S, et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 2014; 15(12): 1311-8.
[] [PMID: 25439689]
Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2018; 378(12): 1107-20.
[] [PMID: 29562156]
Salles GA, Morschhauser F, Solal-Céligny P, et al. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol 2013; 31(23): 2920-6.
[] [PMID: 23835715]
Awan F, Gore L, Gao L, Lager J, Costa L. Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or chronic lymphocytic leukemia. Leuk Lymphoma 2015; 56: 18-8.
Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2021; 22(6): 790-800.
[] [PMID: 33989558]
Zhang X, Wang B, Tao W, et al. Comparison of the efficacy and impact of GEMOX and GDP in the treatment of patients with non-Hodgkin’s lymphoma. J BUON 2021; 25: 1042-9.
[PMID: 32521904]
Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet 2021; 398(10306): 1157-69.
[] [PMID: 34508654]
Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol 2022; 23(1): 91-103.
[] [PMID: 34895487]
Lyons RM, Shtivelband M, Kingsley E, et al. Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab. Leuk Lymphoma 2021; 62(6): 1353-60.
[] [PMID: 33448893]
Advani R, Flinn I, Popplewell L, et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. N Engl J Med 2018; 379(18): 1711-21.
[] [PMID: 30380386]
Umakanthan JM, Iqbal J, Batlevi CL, et al. Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma. Br J Haematol 2019; 184(5): 744-52.
[] [PMID: 30520026]
Antonio J, Grillo LC. White Chimeric anti-CD20 antibody, rituxan, for use in the treatment of chronic lymphocytic leukemia Patent EP1616572B1, 2010.
Popplewell T. Antibodies specific for human cd22 and their therapeutic and diagnostic uses Patent EP1504035B3, 2006.
Andreas B, Padraig M, Anastasios S. Combination of inotuzumab ozogamicin and torisel for the treatment of cancer Patent WO2013088304A1, 2013.
Junming Z. A kind of inhibitor Venetoclax of BCL 2 synthetic method Patent CN107089981A, 2017.
Sundaram S. Formulations of bendamustine Patent US20130253025A1, 2017.
Bruenker P, Herting F, Herter S, et al. Obinutuzumab variants having altered cell death induction Patent WO2017148880A1, 2017.
Polatuzumab vedotin Patent NO2020020I1, 2020.
Marina NG, Pelaez CB. Medical use Patent WO2015181053A1, 2015.
Austad BC, Roe DG. Polymorphs of selinexor Patent US10519139B2, 2019.
Kon NG, Bhimarao D, Kreudenstein TPV. Bispecific cd3 and cd19 antigen binding constructs Patent WO2015006749A2, 2016.
Thennati R, Dwivedi SD, Jadav KJ, Patel VM. JoshiI KC Process for the preparation of idelalisib Patent WO2017221272A1, 2016.
Traverse Y, Ferretti A, Alite M, Ruda P. Philip Process for the preparation of bromodomain inhibitor Patent WO2020023438A2, 2020.
Dimaleate de P. LU92089I2, 2012.
Henteman W, Scott M. Campbell, Bullion R, Rowley, Redman Substituted 2,3-dihydroimidazol[1,2c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis Patent WO2008070150A, 2008.
Weiss M. Sportelli Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor,and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers Patent WO2018049263A1, 2018.
Yao Amorphous umbralisib monotosylate Patent WO2021009509A, 2021.
Raneburger J, Schwarz FX. Pharmaceutical compositions of Ibrutinib Patent WO2015071432A1, 2015.
Zammarchi F, Bertoni F. Combination therapy comprising an anticd19 antibody drug conjugate and a pik3 inhibitor or a secondary agent Patent WO2020249528A1, 2020.
Ujagare A, Kochrekar D, Uzagare M. Process for preparation of gemcitabine hydrochloride Patent US8193354B2, 2012.
Zhang D, Tam SH, Cho M, Nichida M, Shi L, Fung MC. Bispecific antibodies to tnf-alpha and il-1 beta and uses thereof Patent US20210009674A1, 2021.
Wiezorek SJ. Methods of administering chimeric antigen receptor immunotherapy Patent US20190151361A1, 2019.
Austin DJ, Charlton PA, Freedman I, Lee JH. Novel dosing and uses of ofatumumab Patent WO2015162504A, 2015.
Weissman C, Majeti L, Volkmer JP. Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer Patent WO2017181033A1, 2017.
Pattihis N, Panagopoulos P, Lexaki K, Kathiotou G. Dasatinib formulation Patent WO2017144109A1, 2017.
Cheson BD, Chua N, Mayer J, et al. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol 2018; 36(22): 2259-66.
[] [PMID: 29584548]
Cartron G, Hourcade-Potelleret F, Morschhauser F, et al. Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma. Haematologica 2016; 101(2): 226-34.
[] [PMID: 26659915]
Michot JM, Bouabdallah R, Vitolo U, et al. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. Lancet Haematol 2020; 7(9): e649-59.
[] [PMID: 32758434]
Fujimura T, Yamashita-Kashima Y, Kawasaki N, Yoshiura S, Harada N, Yoshimura Y. Obinutuzumab in combination with chemotherapy enhances direct cell death in CD20-positive obinutuzumab-resistant non-Hodgkin lymphoma cells. Mol Cancer Ther 2021; 20(6): 1133-41.
[] [PMID: 33850006]
Morschhauser F, Carlo-Stella C, Offner F, et al. Dual CD20-targeted therapy with concurrent CD20-TCB and obinutuzumab shows highly promising clinical activity and manageable safety in relapsed or refractory B-cell non-Hodgkin lymphoma: preliminary results from a phase Ib trial. Blood 2019; 134 (Suppl. 1): 1584.
Lunning M, Vose J, Nastoupil L, et al. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2019; 134(21): 1811-20.
[] [PMID: 31558467]
Ribeiro ML, Normant E, Garau DR, et al. PS1310 the novel bispecific CD47-CD19 antibody TG-1801 potentiates the activity of Ublituximab-Umbralisib (U2) drug combination in preclinical models of B-NHL. HemaSphere 2019; 3(S1): 598.
Chavez JC, Goldschmidt N, Samaniego F, et al. The combination of umbralisib plus ublituximab is active in patients with relapsed or refractory marginal zone lymphoma (MZL): Results from the phase 2 global unity-NHL Trial. Blood 2021; 138 (Suppl. 1): 45.
Normant E, Ribeiro ML, Profitos-Peleja N, et al. The ublituximab-umbralisib (U2) drug regimen potentiates the activity of the novel CD47-CD19 bispecific antibody, TG-1801, through the activation of the G protein-coupled receptor EBI2/GPR183. Blood 2021; 138 (Suppl. 1): 1196.
Profitós-Pelejà N, Santos JC, Marín-Niebla A, Roué G, Ribeiro ML. Regulation of B-cell receptor signaling and its therapeutic relevance in aggressive B-cell lymphomas. Cancers 2022; 14(4): 860.
[] [PMID: 35205606]
Garrett M, Ruiz-Garcia A, Parivar K, Hee B, Boni J. Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma. J Pharmacokinet Pharmacodyn 2019; 46(3): 211-22.
[] [PMID: 30859374]
Sangha R, Davies A, Dang NH, et al. Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma. J Drug Assess 2017; 6(1): 10-7.
[] [PMID: 28959500]
Goy A, Forero A, Wagner-Johnston N, et al. A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. Br J Haematol 2016; 174(4): 571-81.
[] [PMID: 27101934]
Pirosa MC, Zhang L, Hitz F, et al. A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas. Leuk Lymphoma 2022; 63(1): 117-23.
[] [PMID: 34407735]
Kambhampati S, Fakhri B, Ai WZ, et al. Carfilzomib in combination with bendamustine and rituximab in patients with relapsed or refractory non-hodgkin lymphoma: A phase I trial. Clin Lymphoma Myeloma Leuk 2021; 21(3): 139-46.
[] [PMID: 33478921]
Bertino EM, McMichael EL, Mo X, et al. A phase I trial to evaluate antibody-dependent cellular cytotoxicity of cetuximab and lenalidomide in advanced colorectal and head and neck cancer. Mol Cancer Ther 2016; 15(9): 2244-50.
[] [PMID: 27458141]
Bartlett JB, Wu L, Adams M, Schafer P, Muller G, Stirling D. Lenalidomide and pomalidomide strongly enhance tumor cell killing in vitro during antibody-dependent cellular cytotoxicity (ADCC) mediated by trastuzumab, cetuximab and rituximab. J Clin Oncol 2007; 25(18) (Suppl.): 3023-.
Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol 2019; 37(14): 1188-99.
[] [PMID: 30897038]
Thielen FW, Kersten MJ, Kuizenga P, et al. Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view. Expert Rev Anticancer Ther 2021; 21(12): 1411-22.
[] [PMID: 34428992]
Becnel MR, Nastoupil LJ, Samaniego F, et al. Lenalidomide plus rituximab (R 2) in previously untreated marginal zone lymphoma: subgroup analysis and long‐term follow‐up of an open‐label phase 2 trial. Br J Haematol 2019; 185(5): 874-82.
[] [PMID: 30919940]
Herrera AF, Patel MR, Burke JM, et al. Anti-CD79b antibody-drug conjugate dcds0780a in patients with b-cell non-hodgkin lymphoma: Phase 1 dose-escalation study. Clin Cancer Res 2022; 28(7): 1294-301.
[] [PMID: 34980599]
Herrera AF, Patel MR, Burke JM, et al. A phase i study of the anti-CD79b THIOMABTM-drug conjugate DCDS0780A in patients (pts) with relapsed or refractory B-cell non-hodgkin’s lymphoma (B-NHL). Blood 2017; 130: 4129.
Bourbon E, Salles G. Polatuzumab vedotin: An investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma. Expert Opin Investig Drugs 2020; 29(10): 1079-88.
[] [PMID: 32700972]
Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020; 38(2): 155-65.
[] [PMID: 31693429]
Choi Y, Diefenbach CS. Polatuzumab vedotin: a new target for B cell malignancies. Curr Hematol Malig Rep 2020; 15(2): 125-9.
[] [PMID: 32172360]
Lu D, Gillespie WR, Girish S, et al. Time‐to‐event analysis of polatuzumab vedotin‐induced peripheral neuropathy to assist in the comparison of clinical dosing regimens. CPT Pharmacometrics Syst Pharmacol 2017; 6(6): 401-8.
[] [PMID: 28544534]
Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 2022; 386(4): 351-63.
[] [PMID: 34904799]
Lu T, Gibiansky L, Li X, et al. Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma 2020; 61(12): 2905-14.
[] [PMID: 32705923]
Mariotto S, Tecchio C, Sorio M, et al. Clinical and neurophysiological serial assessments of brentuximab vedotin-associated peripheral neuropathy. Leuk Lymphoma 2019; 60(11): 2806-9.
[] [PMID: 31057013]
Mariotto S, Ferrari S, Monaco S. Brentuximab vedotin-induced peripheral neuropathy: looking at microtubules. J Neurooncol 2018; 137(3): 665-6.
[] [PMID: 29318508]
Kuruvilla J, Ramchandren R, Santoro A, et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 2021; 22(4): 512-24.
[] [PMID: 33721562]
Kebriaei P, Cutler C, de Lima M, et al. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant 2018; 53(4): 449-56.
[] [PMID: 29330398]
Kantarjian HM, Stock W, Cassaday RD, et al. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia in the INO-VATE trial: CD22 pharmacodynamics, efficacy, and safety by baseline CD22. Clin Cancer Res 2021; 27(10): 2742-54.
[] [PMID: 33602684]
O’Brien MM, Ji L, Shah NN, et al. A phase 2 trial of inotuzumab ozogamicin (InO) in children and young adults with relapsed or refractory (R/R) CD22+ B-acute lymphoblastic leukemia (B-ALL): results from Children’s Oncology Group Protocol AALL1621. Blood 2019; 134(S1): 741.
Lee SH, Yoon JH, Min GJ, et al. Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study. Int J Hematol 2022; 115(1): 135-9.
[] [PMID: 34617186]
Cartron G, Blasco H, Paintaud G, Watier H, Le Guellec C. Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol 2007; 62(1): 43-52.
[] [PMID: 17287129]
Wang X, Du W, Zhang X, Li P. The influence of different disease states on rituximab pharmacokinetics. Curr Drug Metab 2020; 21(12): 938-46.
[] [PMID: 32682367]
Iacona I, Lazzarino M, Avanzini MA, et al. Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. Ther Drug Monit 2000; 22(3): 295-301.
[] [PMID: 10850396]
Truffot A, Jourdil JF, Seitz-Polski B, et al. Simultaneous quantification of rituximab and eculizumab in human plasma by liquid chromatography-tandem mass spectrometry and comparison with rituximab ELISA kits. Clin Biochem 2021; 87: 60-6.
[] [PMID: 33096054]
Millet A, Khoudour N, Lebert D, et al. Development, validation, and comparison of two mass spectrometry methods (lc-ms/hrms and lc-ms/ms) for the quantification of rituximab in human plasma. Molecules 2021; 26(5): 1383.
[] [PMID: 33806585]
Di Marco F, Berger T, Esser-Skala W, Rapp E, Regl C, Huber CG. Simultaneous monitoring of monoclonal antibody variants by strong cation-exchange chromatography hyphenated to mass spectrometry to assess quality attributes of rituximab-based biotherapeutics. Int J Mol Sci 2021; 22(16): 9072.
[] [PMID: 34445776]
Kang J, Kim SY, Vallejo D, et al. Multifaceted assessment of rituximab biosimilarity: The impact of glycan microheterogeneity on Fc function. Eur J Pharm Biopharm 2020; 146: 111-24.
[] [PMID: 31841688]
Cerutti ML, Pesce A, Bès C, Seigelchifer M. Physicochemical and biological characterization of RTXM83, a new rituximab biosimilar. BioDrugs 2019; 33(3): 307-19.
[] [PMID: 30927214]
Davids MS, Kuss BJ, Hillmen P, et al. Efficacy and safety of duvelisib following disease progression on ofatumumab in patients with relapsed/refractory CLL or SLL in the DUO crossover extension study. Clin Cancer Res 2020; 26(9): 2096-103.
[] [PMID: 31964785]
Zheng Z, Gao Y, Song Y, et al. Efficacy and safety of duvelisib, a phosphoinositide 3 kinase (PI3K) δ and γ inhibitor, in Chinese patients (pts) with relapsed/refractory follicular lymphoma (R/R FL): A single-arm, open-label, multicenter, phase Ⅱ clinical trial. J Clin Oncol 2021; 39(15) (Suppl.): e19532-2.
Horwitz SM, Foss FM, Porcu P, et al. Duvelisib, an oral dual PI3K-δγ inhibitor, efficacy and safety in patients with relapsed or refractory (RR) peripheral T-cell lymphoma: Rationale for the phase 2 PRIMO trial. Hematol Oncol 2019; 37: 65-6.
Blair HA. Duvelisib: first global approval. Drugs 2018; 78(17): 1847-53.
[] [PMID: 30430368]
Khan SI, Anwar MY, Rafae A, et al. Efficacy and safety of phosphoinositide 3-kinase (pi3k) inhibitors in non-hodgkin’s lymphoma: a systematic review and meta-analysis. Blood 2020; 136(S1): 12-3.
Zinzani PL, Flinn IW, Miller CB, et al. Prognostic and immune-related factors for response to duvelisib in the phase 2 dynamotm clinical trial in iNHL. Blood 2018; 132(S1): 4167.
Gharwan H, Groninger H. Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nat Rev Clin Oncol 2016; 13(4): 209-27.
[] [PMID: 26718105]
Dufner V, Sayehli CM, Chatterjee M, et al. Long-term outcome of patients with relapsed/refractory b-cell non-hodgkin lymphoma treated with blinatumomab. Blood Adv 2019; 3(16): 2491-8.
[] [PMID: 31451445]
Sanders S, Stewart DA. Targeting non-Hodgkin lymphoma with blinatumomab. Expert Opin Biol Ther 2017; 17(8): 1013-7.
[] [PMID: 28532177]
Hijazi Y, Klinger M, Kratzer A, et al. Pharmacokinetic and pharmacodynamic relationship of blinatumomab in patients with non-Hodgkin lymphoma. Curr Clin Pharmacol 2018; 13(1): 55-64.
[] [PMID: 29773068]
Bukhari A, Lee ST. Blinatumomab: a novel therapy for the treatment of non-Hodgkin’s lymphoma. Expert Rev Hematol 2019; 12(11): 909-18.
[] [PMID: 31583919]
Shin N, Li YL, Mei S, et al. INCB040093 is a novel PI3Kδ inhibitor for the treatment of B cell lymphoid malignancies. J Pharmacol Exp Ther 2018; 364(1): 120-30.
[] [PMID: 29127109]
Lampson BL, Brown JR. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. Expert Opin Investig Drugs 2017; 26(11): 1267-79.
[] [PMID: 28945111]
Hanna BS, Roessner PM, Scheffold A, et al. PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia. Leukemia 2019; 33(6): 1427-38.
[] [PMID: 30573773]
Pongas G, Cheson BD. PI3K signaling pathway in normal B cells and indolent B-cell malignancies. Semin Oncol 2016; 43(6): 647-54.
[] [PMID: 28061982]
Cooney JD, Lin AP, Jiang D, et al. Synergistic targeting of the regulatory and catalytic subunits of PI3Kδ in mature B-cell malignancies. Clin Cancer Res 2018; 24(5): 1103-13.
[] [PMID: 29246942]
Krause G, Hassenrück F, Hallek M. Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib. Drug Des Devel Ther 2018; 12: 2577-90.
[] [PMID: 30174412]
Mensah F, Blaize JP, Bryan L. Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date. OncoTargets Ther 2018; 11: 4817-27.
[] [PMID: 30147333]
Narkhede M, Cheson BD. Copanlisib in the treatment of non-Hodgkin lymphoma. Future Oncol 2020; 16(26): 1947-55.
[] [PMID: 32658557]
Dreyling M, Santoro A, Mollica L, et al. Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study. Am J Hematol 2020; 95(4): 362-71.
[] [PMID: 31868245]
Eltantawy A, Vallejos X, Sebea E, Evans K. Copanlisib: an intravenous phosphatidylinositol 3-kinase (PI3K) inhibitor for the treatment of relapsed follicular lymphoma. Ann Pharmacother 2019; 53(9): 954-8.
[] [PMID: 30813760]
Cheson BD, O’Brien S, Ewer MS, et al. Optimal management of adverse events from copanlisib in the treatment of patients with non-Hodgkin lymphomas. Clin Lymphoma Myeloma Leuk 2019; 19(3): 135-41.
[] [PMID: 30584024]
Morgensztern D, McLeod HL. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 2005; 16(8): 797-803.
[] [PMID: 16096426]
Lu JM, Zhang ZZ, Ma X, Fang SF, Qin XH. Repression of microRNA-21 inhibits retinal vascular endothelial cell growth and angiogenesis via PTEN dependent-PI3K/Akt/VEGF signaling pathway in diabetic retinopathy. Exp Eye Res 2020; 190107886.
[] [PMID: 31759996]
Camara AB, Brandao IA. The role of vitamin D and sunlight incidence in cancer. Anticancer Agents Med Chem 2019; 19(11): 1418-36.
[] [PMID: 30864510]
Hałka J. Pixantrone - anticancer drug in the monotherapy of aggressive lymphomas. OncoReview 2020; 10(2): 48-51.
Jezeršek Novaković B, Boltežar L, Novaković A. Current opinion on pixantrone in the treatment of Non-Hodgkin B-Cell Lymphoma. Ther Clin Risk Manag 2021; 17: 183-92.
[] [PMID: 33688197]
Salvatorelli E, Menna P, Paz OG, et al. The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients. J Pharmacol Exp Ther 2013; 344(2): 467-78.
[] [PMID: 23192654]
Waldmann TA. Monoclonal antibodies in diagnosis and therapy. Science 1991; 252(5013): 1657-62.
[] [PMID: 2047874]
Cai HH. Therapeutic monoclonal antibodies approved by FDA in 2020. Clinical Research of Immunology 2021; 4: 1-2.
Lanzavecchia A, Corti D, Sallusto F. Human monoclonal antibodies by immortalization of memory B cells. Curr Opin Biotechnol 2007; 18(6): 523-8.
[] [PMID: 18063358]
Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 23(9): 1073-8.
[] [PMID: 16151394]
Chan L, Karimi N, Morovati S, et al. The roles of neutrophils in cytokine storms. Viruses 2021; 13(11): 2318.
[] [PMID: 34835125]
Intragumtornchai T, Sutheesophon J, Sutcharitchan P, Swasdikul D. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma 2000; 37(3-4): 351-60.
[] [PMID: 10752986]
Zhang M, Gao F, Peng L, et al. Distinct clinical features and prognostic factors of hepatitis C virus-associated non-Hodgkin’s lymphoma: a systematic review and meta-analysis. Cancer Cell Int 2021; 21(1): 524.
[] [PMID: 34627251]
Melenotte C, Mezouar S, Mège JL, Gorvel JP, Kroemer G, Raoult D. Bacterial infection and non-Hodgkin’s lymphoma. Crit Rev Microbiol 2020; 46(3): 270-87.
[] [PMID: 32412856]
Phillips AA, Smith DA. Health disparities and the global landscape of lymphoma care today. Am Soc Clin Oncol Educ Book 2017; 37(37): 526-34.
[] [PMID: 28561692]
Hooper WC, Holman RC, Clarke MJ, Chorba TL. Trends in non-hodgkin lymphoma (NHL) and HIV-associated NHL deaths in the United States. Am J Hematol 2001; 66(3): 159-66.
[<159:AID-AJH1039>3.0.CO;2-2] [PMID: 11279621]
Andrews CN, Gill MJ, Urbanski SJ, Stewart D, Perini R, Beck P. The non‐Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer 2008; 120(S12): 1-39.
Alexander DD, Mink PJ, Adami HO, et al. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer 2007; 120(S12): 1-39.
[] [PMID: 17405121]
Howlader N, Shiels MS, Mariotto AB, Engels EA. Contributions of HIV to non-Hodgkin lymphoma mortality trends in the United States. Cancer Epidemiol Biomarkers Prev 2016; 25(9): 1289-96.
[] [PMID: 27418269]
Tong Q, Liu R, Zhang K, Gao Y, Cui G, Shen W. Can acupuncture therapy reduce preoperative anxiety? A systematic review and meta-analysis. J Integr Med 2021; 19(1): 20-8.
[ ] [PMID: 33288487]
Dreger P. Allogeneic stem cell transplant in non?Hodgkin lymphomas: Still an indication? Hematol Oncol 2021; 39: 100-3.
[ ] [PMID: 34105814]
Hunter BD, Rogalski M, Jacobson CA. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products. Expert Opin Biol Ther 2019; 19(11): 1157-64.
[ ] [PMID: 31342797]
Younes A, Brody J, Carpio C, et al. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. The Lancet Haematology 2019; 6(2): e67-78.
[ ] [PMID: 30642819]
Tavarozzi R, Manzato E. The Role of Bispecific Antibodies in Non-Hodgkin’s Lymphoma: From Structure to Prospective Clinical Use. Antibodies 2022; 11(1): 16.
[] [PMID: 35225874]
Bock AM, Nowakowski GS, Wang Y. Bispecific antibodies for non-Hodgkin lymphoma treatment. Curr Treat Options Oncol 2022; 23(2): 155-70.
[ ] [PMID: 35182296]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy